{"version":"1.0","provider_name":"Journal of Medical Ethics blog","provider_url":"https:\/\/blogs.bmj.com\/medical-ethics","author_name":"Hazem Zohny","author_url":"https:\/\/blogs.bmj.com\/medical-ethics\/author\/zohnyh\/","title":"A Novel Approach to Compassionate Use Allocation - Journal of Medical Ethics blog","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"vCp1fgpPoE\"><a href=\"https:\/\/blogs.bmj.com\/medical-ethics\/2018\/06\/30\/a-novel-approach-to-compassionate-use-allocation\/\">A Novel Approach to Compassionate Use Allocation<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/blogs.bmj.com\/medical-ethics\/2018\/06\/30\/a-novel-approach-to-compassionate-use-allocation\/embed\/#?secret=vCp1fgpPoE\" width=\"600\" height=\"338\" title=\"&#8220;A Novel Approach to Compassionate Use Allocation&#8221; &#8212; Journal of Medical Ethics blog\" data-secret=\"vCp1fgpPoE\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script type=\"text\/javascript\">\n\/* <![CDATA[ *\/\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/\/# sourceURL=https:\/\/blogs.bmj.com\/medical-ethics\/wp-includes\/js\/wp-embed.min.js\n\/* ]]> *\/\n<\/script>\n","description":"By\u00a0Lisa Kearns, Alison S. Bateman-House, Arthur L. Caplan, J. Russell Teagarden When seriously ill patients cannot enroll in clinical trials and have run out of treatment options, they may ask pharmaceutical manufacturers for \u201ccompassionate use\u201d of their drugs in development, knowing that the drugs are experimental and may not help. These are tricky decisions for [...]Read More..."}